01Milk excretion after Motilium 10 mg
Domperidone is excreted in human breast milk after oral Motilium 10 mg. Breast-fed infants receive less than 0.1% of the maternal weight-adjusted dose. Cardiac effects in the infant cannot be excluded. The decision is whether to discontinue breast-feeding or to discontinue Motilium. A 10 mg tablet is one labelled strength on that carton.
| Pharmacy | Strength / count | What to expect at the counter | Official page |
|---|---|---|---|
| Walgreens | 10 mg tablet | Not a routine US retail product | Walgreens pharmacy |
| Meijer | 10 mg tablet | No published US cash price exists | Meijer pharmacy |
| Safeway | 10 mg tablet | Labelled by Health Canada and the EMA, not the FDA | Safeway pharmacy |
| H-E-B | 10 mg tablet | QT and lactation cautions apply wherever it is dispensed | H-E-B pharmacy |
Sources and how this letter was sealed
- EMA / CMDh 2014 domperidone referral: 10 mg up to TID, max 1 week, cardiac risk groups.
- Motilium 10 mg SmPC (e.g. Malta MA): before meals, skip missed dose, hepatic contraindication, QT study 3.4 msec at 80 mg/day; milk <0.1% maternal dose.
- FDA, Information about Domperidone: not approved for any human use in the U.S.; compounding does not meet 503A/503B; 2004 and 2012 lactation warnings.
- LactMed: not FDA-approved; no licensed galactagogue dose.
Method in brief: open primary sources, annotate against the current FDA label, countersign by Dr. Nora Lindqvist, MD, then seal with a dated review. Full walk-through on the method page and editorial standards.
How to cite this page - Vancouver style
Juvia Pharma Drug Reference. Motilium 10 mg has no FDA-approved US tablet [Internet]. Stockholm: Juvia Pharma; 21 October 2026 [cited 2026 Aug 21]. Available from: https://juviapharma.com/letters/domperidone/